Toni Choueiri, MD· @DrChoueiri · X·· 1 day agoScore45
Body
And now @Maroto5Pablo reporting long term follow-up from phase Ib/II #EV-103 study.
Consistent with prior reports:
EV+P demonstrated sustained responses and survival, with a manageable safety profile.
#ESMO26 #Day2 @myESMO @OncoAlert
226 views · 5 likes · 4 reposts · 0 replies
Conference abstracts
4740ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial
Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K
https://esmocongress.esmo.orgSource: Toni Choueiri, MD · x.com